Question 1

What are the potential side effects of the treatments being tested?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases clinical trial (NCT06238921). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this trial compare to my current treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases clinical trial (NCT06238921). Contact the study team or your healthcare provider for specific answers.

Question 3

What will my participation involve in terms of visits and treatments?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases clinical trial (NCT06238921). Contact the study team or your healthcare provider for specific answers.

Question 4

Are there any specific eligibility requirements I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases clinical trial (NCT06238921). Contact the study team or your healthcare provider for specific answers.

Question 5

How will my health be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases clinical trial (NCT06238921). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if I experience side effects or my condition worsens?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases clinical trial (NCT06238921). Contact the study team or your healthcare provider for specific answers.

What this study is about